STAT columnist Adam Feuerstein analyzes new clinical data for ImmunityBio's cancer drug Anktiva, arguing that the results contradict founder Patrick Soon-Shiong's claims of survival benefits in advanced lung cancer patients. The article highlights the drug's modest commercial performance for bladder cancer and notes the recent approval of a superior competitor by Johnson & Johnson.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.